- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02447991
Rizatriptan for Episodic Dizziness in Vestibular Migraine
A Phase II/III Trial on Rizatriptan for Vestibular Migraine
Suffering from dizzy spells and migraine headaches?
Vestibular Migraine (VM), a newly recognized type of migraine that causes bouts of dizziness.
University of California, Los Angeles (UCLA) and The Mayo Clinic is seeking people with VM to participate in a research study. The purpose of this study is to look at the natural history of VM and learn more about common symptoms. Investigators also want to learn the effects, both positive and negative, of the commonly used migraine drug, rizatriptan, when it is used for spells of dizziness in people with VM.
Patients may be eligible to participate if:
- Patients are between the ages of 18 & 65
- Patients have a history of vestibular migraine
- Patients are able to maintain a vestibular symptom diary
The study includes 3 visits with compensation. All participants must complete questionnaires on dizziness, headache symptoms, general health and well-being, mental health, and a questionnaire on patient's satisfaction with study medication.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary Specific Aim is to conduct the first successful controlled study of a treatment for Vestibular Migraine. The investigators hypothesize that rizatriptan will be superior to a look alike inactive capsule for:
1a. Reducing the severity and duration of vertigo attacks in patients with Vestibular Migraine,
1b. Reducing the severity of symptoms commonly associated with vertigo attacks in patients with Vestibular Migraine (e.g., nausea, vomiting, motion sensitivity, gait disturbance, headache, light and sound sensitivity), and
1c. Improving treatment satisfaction and health-related quality of life in patients with Vestibular Migraine, and that
1d. Rizatriptan will be well tolerated by patients with Vestibular Migraine.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Must answer yes to be eligible
- Are between the ages of 18 & 65
- Have a history of vestibular migraine
Are able to maintain a vestibular symptom diary
History that fulfills all criteria for VM as defined in Table 1, except that attacks must last at least 2 hours.
- At least 5 episodes
- A current or past history of migraine without aura or migraine with aura
- Vestibular symptoms of moderate or severe intensity lasting at least 2 hours
50% of episodes are associated with at least one of the following:
Headache with at least 2 of:
- unilateral location
- pulsating quality
- moderate or severe intensity,
- aggravation by routine physical activity
- Experience photophobia and phonophobia
- Experience visual aura
- Episodes must have a spontaneous onset and resolution without associated hearing loss or interictal neurotologic deficits.
- Other causes of vestibular symptoms ruled out by appropriate clinical investigations.
- Current medication list compatible with Concomitant Medications below.
- Able to maintain a Vestibular Symptom Diary and complete all other study procedures.
Exclusion Criteria: Must answer no to be eligible.
- Ménière's disease by The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS) criteria60.
- Migraine with brainstem aura (formerly basilar-type migraine) by the International Classification of Headache Disorders (ICHD-3) criteria.14
- Ischemic heart disease, coronary artery vasospasm, uncontrolled hypertension.
- History of stroke or transient ischemic attack.
- History of using rizatriptan specifically to treat vestibular attacks.
- History of adverse response to triptans or intolerance to lactose.
- Women who are pregnant or breastfeeding.
- Unable or unwilling to comply with study requirements for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
During the Treatment Phase, three placebo capsules will be administered to each subject.
One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
|
During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
Other Names:
|
Experimental: Rizatriptan
During the Treatment Phase, three Rizatriptan capsules will be administered to each subject.
One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
|
During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
Episodes in which a reduction in symptom severity from moderate/severe (rating 2/3) at time of taking study medication to none/mild rating (0/1) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Symptoms of Unsteadiness/Dizziness Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
Episodes of unsteadiness/dizziness in which a reduction in symptom severity from moderate/severe (rating 2/3) to none/mild rating (0/1) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Episodes With Complete Relief of Vertigo as Vestibular Symptom
Time Frame: 1 hour after taking study medication
|
The number of episodes in which complete relief of vertigo symptoms (rating 0) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Complete Relief of Unsteadiness/Dizziness Vestibular Symptoms
Time Frame: 1 hour after taking study medication
|
The outcome was the number of episodes in which complete relief of symptoms of unsteadiness/dizziness (rating 0) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms (vertigo and unsteadiness/dizziness) wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Headache Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
The outcome was the number of episodes in which a reduction of headache symptoms (rating 0) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Photophobia/Phonophobia Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
The outcome was the number of episodes in which a reduction of symptoms (rating 0/1) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Sensitivity to Motion Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
The outcome was the number of episodes in which a reduction of sensitivity to motion symptoms (rating 0/1) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Episodes With Nausea/Vomiting Reduced From Moderate/Severe to None/Mild
Time Frame: 1 hour after taking study medication
|
The outcome was the number of episodes in which a reduction of symptoms (rating 0/1) was achieved.
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
1 hour after taking study medication
|
Satisfaction With Treatment
Time Frame: 48 hour after taking study medication
|
Treatment Satisfaction Questionnaire for Medication (TSQM) assessed four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction).
|
48 hour after taking study medication
|
Health-Related Quality of Life
Time Frame: 48 hour after taking study medication
|
Short Form Survey - 12 (SF-12) assessed physical and mental well-being after taking study medication for each episode, generating composite scores in each domain from 12 questions.
The range is 0-100 with higher scores indicated better physical and mental health functioning.
|
48 hour after taking study medication
|
Side Effects
Time Frame: 48 hour after taking study medication
|
Number of adverse events experienced by participants.
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 categorizes all domains of physical and psychological side effects, grading them 1-mild, 2-moderate, 3-severe, 4-life threatening, 5-death.
|
48 hour after taking study medication
|
Episodes With Sustained Reduction in Severity of Vertigo From Moderate/Severe to None/Mild Without Additional Medication
Time Frame: 24 hours after taking study medication
|
Episodes in which participants achieved reduction of symptoms (from rating 2-3 to 0-1).
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Episodes With Sustained Reduction in Severity of Dizziness/Unsteadiness From Moderate/Severe to None/Mild Without Additional Medication
Time Frame: 24 hours after taking study medication
|
Episodes in which participants achieved reduction of symptoms (from rating 2-3 to 0-1).
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Episodes With Headache Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
Time Frame: 24 hours after taking study medication
|
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Episodes With Photophobia/Phonophobia Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
Time Frame: 24 hours after taking study medication
|
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Episodes With Sensitivity to Motion Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
Time Frame: 24 hours after taking study medication
|
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Episodes With Nausea/Vomiting Symptoms Reduced From Moderate/Severe (3/4) to None/Mild (0/1) Without Additional Medication
Time Frame: 24 hours after taking study medication
|
After taking study medication participants reported symptoms using a patient self-report of the severity of vestibular symptoms wherein 0=no symptoms, 1=mild symptoms (no interference with activities), 2=moderate symptoms (had to alter some activities), and 3=severe symptoms (had to stop most or all activities).
|
24 hours after taking study medication
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert W Baloh, M.D., University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Otorhinolaryngologic Diseases
- Labyrinth Diseases
- Ear Diseases
- Vestibular Diseases
- Headache Disorders, Primary
- Headache Disorders
- Vertigo
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Serotonin Agents
- Serotonin Receptor Agonists
- Rizatriptan
Other Study ID Numbers
- IRB12-001549
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vestibular Migraine
-
Ege UniversityCompletedVestibular Migraine | Vestibular Disorder | Migraine Variant
-
Otolith LabsMCRAEnrolling by invitationVestibular Migraine | Migraine Associated VertigoUnited States
-
Massachusetts Eye and Ear InfirmaryWithdrawnMigraine Disorders | Vestibular Diseases | Vestibular MigraineUnited States
-
University of MalayaNot yet recruitingVestibular MigraineMalaysia
-
Pamukkale UniversityRecruiting
-
Assiut UniversityNot yet recruiting
-
First Affiliated Hospital of Jiaxing UniversityNot yet recruiting
-
University of California, San FranciscoEli Lilly and CompanyRecruiting
-
Rahma Alaa KamelEnrolling by invitation
-
Mayo ClinicCompletedVestibular Migraine | Chronic Subjective DizzinessUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States